| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.044 | 0.4 |
| mRNA | KU-0063794 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | Dasatinib | FIMM | pan-cancer | AAC | 0.16 | 0.4 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | 0.052 | 0.4 |
| mRNA | Gemcitabine | GDSC1000 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | -0.029 | 0.4 |